This Biotech Works On All Phases Of Breast Cancer, From Prevention To Post Surgery

Mark Goldston, Executive Chairman of Atossa Therapeutics ATOS, recently participated in Benzinga's Virtual HealthCare Summit 2024.

Atossa is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Its therapies are involved in prevention, neoadjuvant treatment – or treatment before surgery – and adjuvant treatment or post-surgery treatment.

The company is expecting to report key data at a conference in San Diego in early April.

Learn more here:

Featured photo by Angiola Harry on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.